UCB PHARMA SA

UCB PHARMA SA logo
🇧🇪Belgium
Ownership
Public, Subsidiary
Established
1928-01-01
Employees
9K
Market Cap
$34.9B
Website
https://www.ucb-iberia.com/home

A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy

Phase 3
Completed
Conditions
Interventions
First Posted Date
2006-07-10
Last Posted Date
2024-03-22
Lead Sponsor
UCB Pharma
Target Recruit Count
551
Registration Number
NCT00350103

Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes

Phase 1
Completed
Conditions
Interventions
First Posted Date
2006-06-29
Last Posted Date
2022-04-08
Lead Sponsor
UCB Pharma SA
Target Recruit Count
25
Registration Number
NCT00345800

UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)

First Posted Date
2006-06-28
Last Posted Date
2016-09-02
Lead Sponsor
UCB Pharma
Target Recruit Count
516
Registration Number
NCT00345475
Locations
🇺🇸

INC Research, Wilmington, North Carolina, United States

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

Phase 3
Completed
Conditions
Interventions
First Posted Date
2006-06-06
Last Posted Date
2018-08-07
Lead Sponsor
UCB Pharma
Target Recruit Count
233
Registration Number
NCT00333788

Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2006-05-24
Last Posted Date
2015-03-18
Lead Sponsor
UCB Pharma
Target Recruit Count
46
Registration Number
NCT00329420

Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2006-05-24
Last Posted Date
2019-05-06
Lead Sponsor
UCB Pharma
Target Recruit Count
71
Registration Number
NCT00329303

Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam

Completed
Conditions
First Posted Date
2006-04-27
Last Posted Date
2012-05-25
Lead Sponsor
UCB Pharma
Target Recruit Count
600
Registration Number
NCT00319605

Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen

Phase 3
Completed
Conditions
First Posted Date
2006-04-18
Last Posted Date
2013-12-16
Lead Sponsor
UCB Pharma
Target Recruit Count
403
Registration Number
NCT00315523

Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab

First Posted Date
2006-03-29
Last Posted Date
2018-08-07
Lead Sponsor
UCB Pharma
Target Recruit Count
539
Registration Number
NCT00308581

Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2006-03-28
Last Posted Date
2011-08-31
Lead Sponsor
UCB Pharma
Target Recruit Count
16
Registration Number
NCT00307931
© Copyright 2024. All Rights Reserved by MedPath